Compare IMMR & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | SLGL |
|---|---|---|
| Founded | 1993 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.5M | 240.3M |
| IPO Year | 1999 | 2016 |
| Metric | IMMR | SLGL |
|---|---|---|
| Price | $6.78 | $74.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $13.50 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 601.9K | 24.2K |
| Earning Date | 04-13-2026 | 05-22-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $35,013,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | $339.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $6.96 |
| 52 Week High | $8.00 | $97.97 |
| Indicator | IMMR | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 54.62 | 51.24 |
| Support Level | $6.30 | $70.05 |
| Resistance Level | $6.91 | $75.00 |
| Average True Range (ATR) | 0.29 | 4.78 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 62.92 | 39.73 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.